Ionis Pharmaceuticals Inc (IONS) Position Raised by BNP Paribas Arbitrage SA

BNP Paribas Arbitrage SA boosted its position in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 31.4% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 13,881 shares of the company’s stock after buying an additional 3,319 shares during the quarter. BNP Paribas Arbitrage SA’s holdings in Ionis Pharmaceuticals were worth $612,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the stock. BB Biotech AG raised its holdings in Ionis Pharmaceuticals by 4.7% during the 1st quarter. BB Biotech AG now owns 8,516,334 shares of the company’s stock valued at $375,400,000 after buying an additional 380,000 shares during the last quarter. Wells Fargo & Company MN raised its holdings in Ionis Pharmaceuticals by 3.5% during the 1st quarter. Wells Fargo & Company MN now owns 1,142,168 shares of the company’s stock valued at $50,346,000 after buying an additional 38,839 shares during the last quarter. Geode Capital Management LLC increased its position in Ionis Pharmaceuticals by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 1,074,130 shares of the company’s stock valued at $54,028,000 after purchasing an additional 24,499 shares during the period. Tocqueville Asset Management L.P. increased its position in Ionis Pharmaceuticals by 19.3% during the 4th quarter. Tocqueville Asset Management L.P. now owns 841,724 shares of the company’s stock valued at $42,339,000 after purchasing an additional 136,317 shares during the period. Finally, Farallon Capital Management LLC increased its position in Ionis Pharmaceuticals by 43.3% during the 4th quarter. Farallon Capital Management LLC now owns 645,000 shares of the company’s stock valued at $32,444,000 after purchasing an additional 195,000 shares during the period. Institutional investors own 91.07% of the company’s stock.

A number of brokerages have issued reports on IONS. ValuEngine raised shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, March 8th. TheStreet downgraded shares of Ionis Pharmaceuticals from a “c” rating to a “d+” rating in a research report on Tuesday, February 27th. Zacks Investment Research downgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 28th. BidaskClub raised shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, March 9th. Finally, BMO Capital Markets boosted their price objective on shares of Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, February 28th. Four equities research analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. Ionis Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $52.83.

NASDAQ:IONS opened at $42.95 on Friday. The stock has a market capitalization of $5.53 billion, a PE ratio of 536.88 and a beta of 2.48. The company has a current ratio of 5.38, a quick ratio of 5.33 and a debt-to-equity ratio of 1.59. Ionis Pharmaceuticals Inc has a 1-year low of $39.07 and a 1-year high of $65.51.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Friday, May 4th. The company reported ($0.01) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.10. The firm had revenue of $144.40 million for the quarter, compared to the consensus estimate of $144.01 million. Ionis Pharmaceuticals had a negative net margin of 2.00% and a negative return on equity of 3.06%. The company’s revenue was up 24.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.03 EPS. analysts forecast that Ionis Pharmaceuticals Inc will post -0.04 EPS for the current fiscal year.

In other news, Chairman Stanley T. Crooke sold 13,962 shares of the company’s stock in a transaction dated Tuesday, April 17th. The shares were sold at an average price of $44.40, for a total value of $619,912.80. Following the sale, the chairman now directly owns 56,714 shares of the company’s stock, valued at approximately $2,518,101.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Frederick T. Muto sold 15,000 shares of the company’s stock in a transaction dated Thursday, May 31st. The stock was sold at an average price of $46.45, for a total transaction of $696,750.00. Following the completion of the sale, the director now directly owns 22,127 shares in the company, valued at $1,027,799.15. The disclosure for this sale can be found here. Insiders sold a total of 58,462 shares of company stock worth $2,651,113 over the last ninety days. Insiders own 2.13% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply